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Abstract  The  most  used  and  reliable  indicator  of  equine  infectious  anemia  virus  (EIAV)  infec-
tion is  the  detection  of  its  speciﬁc  antibodies  in  horse  serum.  In  the  present  study,  the
performance  of  two  commercial  ELISA  tests  for  the  detection  of  EIAV  antibodies  as  well  as
the potential  advantages  of  their  use  as  an  EIAV  infection  screening  tool  were  evaluated  in  302
horse serum  samples.  Both  ELISA  assays  showed  100%  diagnostic  sensitivity,  and  92.3--94.3%
diagnostic  speciﬁcity.  Discordant  results  were  analyzed  by  immunoblot.  The  results  showed
that both  ELISA  tests  are  very  efﬁcient  at  detecting  EIAV  infected  animals,  allowing  to  identify
a higher  number  of  positive  horse  cases.  Thus,  ELISA  assays  can  be  useful  tools  in  EIA  control
and eradication.
©  2014  Asociación  Argentina  de  Microbiología.  Published  by  Elsevier  España,
S.L.U. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
PALABRAS  CLAVE
Elisa;
Virus  de  la  anemia
Eﬁcacia  de  ensayos  de  ELISA  comerciales  para  el  screening  de  infección  por  el  virus
de  la  anemia  infecciosa  equinaor  de  la  infección  por  el  virus  de  la  anemia  infecciosa  equina  (Equine
V)  es  la  detección  de  anticuerpos  especíﬁcos  en  el  suero  del  caballo.
valuó  la  capacidad  de  detección  de  anticuerpos  contra  EIAV  de  dos
les  utilizando  302  muestras  de  suero  equino,  así  como  las  ventajas
 herramientas  de  screening.  Ambos  ensayos  de  ELISA  presentaron
óstica  y  una  especiﬁcidad  diagnóstica  del  orden  de  92,3  a  94,3  %.infecciosa  equina;
Diagnóstico
Resumen  El  mejor  indicad
infectious  anemia  virus,  EIA
En el  presente  trabajo  se  e
equipos  de  ELISA  comercia
potenciales  de  su  uso  como
100 %  de  sensibilidad  diagn∗ Corresponding author.
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BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Las  muestras  discordantes  fueron  analizadas  por  inmunoblot.  Los  resultados  mostraron  que  las
dos pruebas  ELISA  son  muy  eﬁcientes  para  detectar  animales  infectados  por  EIAV,  al  permitir
identiﬁcar  un  mayor  número  de  animales  positivos  que  la  prueba  de  inmunodifusión  en  gel  de
agar, oﬁcialmente  aprobada  en  la  República  Argentina  para  la  certiﬁcación  de  los  animales.
Las pruebas  de  ELISA  constituyen  herramientas  muy  útiles  en  los  programas  de  control  y  de
erradicación  de  la  infección  por  EIAV.
© 2014  Asociación  Argentina  de  Microbiología.  Publicado  por  Elsevier  España,
S.L.U. Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dEquine  infectious  anemia  (EIA)  is  a  blood-borne  infection
hat  affects  horses  and  other  equids,  which  is  caused  by
he  Equine  infectious  anemia  virus  (EIAV),  genus  Lentivirus
f  the  family  Retroviridae. The  disease  has  a  severe  eco-
omic  impact  on  the  equine  industry,  and  thus  falls  under
 regulatory  control  program  in  many  countries,  including
rgentina9.
One  of  the  key  measures  to  prevent  the  transmission
f  EIAV  infection  is  the  identiﬁcation  and  segregation  of
nfected  horses.3 So  far,  the  only  reliable  indicator  of
IAV  infection  has  been  the  presence  of  speciﬁc  antibodies
gainst  the  envelope  glycoproteins  (gp90  and  gp45)  and/or
he  major  core  protein  (p26)  of  EIAV.  The  agar  gel  immunod-
ffusion  (AGID)  test,  designed  by  Coggins  in  19722,  identiﬁes
ntibodies  against  the  major  core  protein  p26  of  EIAV,  and
onstitutes  the  gold  standard  test,  approved  for  the  diagno-
is  of  EIA  by  both  national9 and  international6 authorities.
his  test  is  inexpensive,  easy  to  perform  and  highly  speciﬁc;
et,  the  turnover  time  is  more  than  48  h.  There  are  several
eports  describing  the  enzyme-linked  immunosorbent  assay
ELISA)  tests  using  puriﬁed  viral  proteins,  recombinant  pro-
eins  and/or  synthetic  peptides  as  antigen;  all  have  shown
n  excellent  correlation  with  the  AGID  assay,  and  some  of
hem,  a  higher  sensitivity3.
The  purpose  of  this  study  was  to  evaluate  the  perfor-
ance  of  two  commercial  ELISA  tests  for  the  detection  of
IAV  antibodies,  as  well  as  the  potential  advantages  of  their
se  as  an  EIA  screening  tool.
In  this  study,  302  individual  horse  serum  samples  were
sed.  The  horses  were  from  14  premises  located  in  the
rovinces  of  Corrientes,  Chaco  and  Santa  Fe,  in  the  north-
astern  and  central  region  of  Argentina,  an  EIA  endemic
rea.4 Blood  for  serum  was  obtained  from  horses  by  jugu-
ar  venipuncture  according  to  the  guidelines  described  in  the
anual  for  Use  and  Care  of  Experimental  Animals,  issued  and
pproved  institutionally  by  INTA.  All  samples  were  tested
y  two  ELISA  methods  [ELISA-A  (Ingezim  anemia  equina,
ngenasa,  Spain),  and  ELISA-B  (Eradikit  EIAV,  In3diagnostic,
taly]  and  by  the  AGID  test  [INCUINTA  (rp26  IDGA  Incuinta
IE,  Incuinta,  Argentina).  The  AGID  test  was  considered  as
he  standard  for  comparison.  All  assays  were  performed
ccording  to  the  manufacturers’  instructions.  The  degree
f  agreement  between  each  pair  of  tests  was  determined  by
   test  (http://graphpad.com/quickcalcs/kappa2/).
Both  ELISA  assays  showed  higher  sensitivity  than  the  AGID
est.  The  proportion  of  positive  animals  detected  was  35%,
6%  and  31%  for  the  ELISA-A,  the  ELISA-B  and  the  AGID  tests,
espectively.  Both  ELISAs  had  a  high  degree  of  agreement
ith  the  AGID  test,  and,  in  addition,  were  even  able  to
d
h
petect  antibodies  in  samples  that  would  have  been  recorded
s  negative  when  tested  by  AGID  (Table  1).  The  Kappa
oefﬁcients  were:  AGID  test  versus  ELISA-A  test,  0.910;
GID  test  versus  ELISA-B  test,  0.881;  between  both  ELISAs
ests,  0.971.  In  all  cases,  they  indicated  a  high  concordance
evel.  Diagnostic  speciﬁcity  was  94.3%  for  ELISA-A,  and  92.3%
or  ELISA-B.  In  order  to  identify  the  true  positive  samples,
oth  ELISA  (A  and/or  B)  positive  and  AGID  negative  sam-
les  were  analyzed  by  immunoblot  (rp26-WB)1 (Table  2).
ight  out  of  17  (47%)  AGID  negative  samples  were  scored  as
ositive  according  to  their  reactivity  to  the  rp26-WB  test.
ive  out  of  12  ‘‘negative  AGID/positive  ELISA-A’’  samples,
 out  of  16  ‘‘negative  AGID/positive  ELISA-B’’,  and  3  out
f  4 ‘‘negative  ELISA-A/positive  ELISA-B’’  samples,  tested
ositive  by  the  rp26-WB  test.  One  sample  (ID:  94),  which
howed  an  inconclusive  result  by  ELISA-B,  tested  negative
y  the  rp26-WB  test.  These  results  show  a  higher  sensitiv-
ty  of  the  ELISA-A  and  ELISA-B  tests  than  of  the  AGID  test.
LISA-B  detected  more  positive  samples  than  ELISA-A,  prob-
bly  due  to  the  fact  that  ELISA-B  targets  antibodies  to  both
he  envelope  and  core  EIAV  antigens  whereas  ELISA-A  targets
ntibodies  to  the  p26  core  protein  of  EIAV  only.
Currently,  there  is  no  vaccine  or  treatment  for  EIA,  there-
ore,  the  control  strategy  consists  in  the  detection  and
egregation  of  infected  animals;  thus,  a  reliable  diagnos-
ic  test  is  a  crucial  issue.  The  AGID  test  is  still  the  only  one
o  be  internationally  recognized  as  the  gold  standard  for  the
iagnosis  of  EIA-infected  animals,  and  is  the  prescribed  test
or  international  trade  and  movement  of  horses6.  Yet,  even
hough  the  speciﬁcity  of  the  AGID  test  is  very  high,  its  sensi-
ivity  is  lower  than  that  of  other  tests,  especially  to  detect
ow  levels  of  speciﬁc  antibodies3.  The  ELISA  test  has  the
dvantage  of  allowing  efﬁcient  and  accurate  testing  of  large
umbers  of  serum  samples  within  a  relatively  short  time,
nd  of  results  admitting  an  objective  calculation  if  assay
olor  development  is  measured  with  a  spectrophotometer.
n  concordance  with  previous  reports  recently  reviewed  by
ssel  and  others6, both  ELISA  tests  used  in  our  study  have  a
igher  sensitivity  than  the  AGID  test,  and,  in  addition,  47%
8/17)  of  ELISA  positive-AGID  negative  samples  were  con-
rmed  as  EIA  positive  by  WB.  However,  false  positive  results
ere  also  found:  6%  (7/105)  by  ELISA-A  and  7%  (8/109)  by
LISA-B;  therefore,  a  sample  detected  as  positive  by  ELISA
ust  be  conﬁrmed  by  AGID,  the  ‘‘gold  standard’’  test5.
The  use  of  a  combination  of  tests  to  more  accurately
iagnose  EIAV  infections  has  been  already  proposed5,7,8.  The
iagnostic  algorithm  consists  in  using  the  advantage  of  the
igher  sensitivity  of  ELISA  tests  to  identify  the  EIA  negative
opulation,  the  increased  power  (speciﬁcity)  of  the  AGID
ELISA  test  for  the  screening  of  EIAV  27
Table  1  Equine  infectious  anemia  virus  antibody  detection  by  AGID  and  ELISA  tests  in  302  horse  serum  samples.
ELISA-A  ELISA-B  Total
Negative  Positive  Negative  Positive
AGID
Negative  197  12  193a 16  209  (69%)
Positive 0  93  0  93  93  (31%)
Total 197  (65%)  105  (35%)  193  (64%)  109  (36%)  302  (100%)
a One sample with a doubtful result (#94) was included as negative.
Table  2  rp26-western  blot  (rp26-WB)  analysis  of  samples  showing  AGID  and  ELISA  A  and  B  discordant  results.
Sample  AGIDa ELISA  Ab ELISA  Bc rp26-WBd
69  −  −  +  +
9 −  −  +  +
27 −  +  +  +
39 −  −  +  +
42 −  +  +  +
47 −  +  +  +
68 −  −  +  −
94 −  −  Doubtful  −
98 −  +  +  +
199 −  +  +  −
200 −  +  +  −
210 −  +  +  −
211 −  +  +  −
217 −  +  +  +
225 −  +  +  −
228 −  +  +  −
229 −  +  +  −
a rp26 IDGA Incuinta AIE (Incuinta).
b Ingezim anemia equina (Ingenasa).
c
E
E
‘
i
m
E
P
d
w
c
M
C
dEradikit EIAV (In3diagnostic).
d Alvarez et al. (2007); − negative; + positive.
test  to  take  actions  (segregate/sacriﬁce  of  AGID  positive
horses),  and  the  use  of  immunoblot  tests  in  the  uncommon
samples  yielding  ELISA  positive/AGID  negative  results.  Most
samples  that  are  positive  by  ELISA  tests  and  negative  by
the  AGID  test,  react  with  both  the  envelope  glycoproteins
and  the  major  core  protein  (p26)  of  EIAV,  when  tested  by
immunoblot.  Fortunately,  equids  only  presenting  the  p26
antigen  of  EIAV  by  immunoblot  (and  judged  as  not  speciﬁc
for  EIA)  are  but  rarely  encountered  in  equid  populations.
False  positive  results  with  ELISA  tests  might  be  explained  as
a  cross-reaction  to  a  related  antigen5.
So  far,  testing  for  EIAV  infection  is  mandatory  for  the
national  and  international  movement  of  horses.  Reliable
data  on  the  true  prevalence  of  the  infection  in  Argentina
is  not  yet  available.  Anecdotal  data  from  diagnostic  labo-
ratories  indicates  that  Argentina  has  an  endemic  area  in  its
north-eastern  region,  a  low  and  very  low  prevalence  area
in  the  center,  and  is  free  of  infection  in  the  south4. The
obtained  data  (31%,  93/302)  contributes  to  the  knowledge
of  the  EIA  infection  in  Argentina,  conﬁrming  the  high  preva-
lence  of  EIA  in  the  horse  population  of  the  north-eastern  and
central  regions  of  our  country.
R
dAlthough  the  results  in  this  work  are  preliminary,  the
LISA  tests  evaluated  seem  to  be  very  effective  to  detect
IA  infected  animals,  as  both  tests  allowed  to  identify  more
‘positive’’  animals  than  the  AGID  test,  enabling  the  early
dentiﬁcation  of  potential  ‘‘Trojan  horses’’  capable  of  trans-
itting  the  EIAV  to  susceptible  animals.
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